Steadybase.

Mesoblast Ltd.

Website LinkedIn
  • MESO · Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • Melbourne, Victoria, C3
  • 108 employees
  • CIK 0001345099

Updated from SEC filings through

Top things to know

Executives

Mesoblast Ltd is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Melbourne, Victoria, C3. It trades as MESO on Nasdaq. Revenue was $17.2M in the fiscal year ending June 30, 2025, +191.4% from the year before. It reported about 108 employees.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue $17.2M
20-F, 2025-08-29
$5.9M
20-F, 2025-08-29
$7.5M
20-F, 2025-08-29
$10.2M
20-F, 2024-08-29
$7.4M
20-F, 2023-08-31
Operating income Not on file Not on file Not on file Not on file Not on file
SG&A Not on file Not on file Not on file Not on file Not on file
Net income -$102M
20-F, 2025-08-29
-$88.0M
20-F, 2025-08-29
-$81.9M
20-F, 2025-08-29
-$91.3M
20-F, 2024-08-29
-$98.8M
20-F, 2023-08-31

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Silviu Itescu
founder at mesoblast
CEO and Managing Director Form 3, April 1, 2026
James Michael Obrien Chief Financial Officer Form 4, July 9, 2026
Eric Allen Rose Chief Medical Officer,Director Form 3, March 18, 2026

What Mesoblast Ltd does

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Press release "About" paragraph, 10-K for the year ending October 29, 2026

Shares and governance

Shares outstanding 1.30 billion (as of June 30, 2026) 20-F, August 27, 2026
Auditor PricewaterhouseCoopers (Melbourne, Australia) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
April 10, 2026 Gregory George
Director
Buy 7,910,962 $11.4M Form 4, April 13, 2026
April 10, 2026 Gregory George
Director
Buy 8,305,962 $26.1M Form 4, April 10, 2026

Recent 8-K events

No 8-K filings on file.

Frequently asked questions about Mesoblast Ltd

What does Mesoblast Ltd do?
In its own words, from Item 1 of its 10-K: "Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process."
What is Mesoblast Ltd's revenue?
$17.2M for the fiscal year ending June 30, 2025, from its 20-F filed August 29, 2025.
Is Mesoblast Ltd profitable?
Mesoblast Ltd reported net income of -$102M for the fiscal year ending June 30, 2025.
How many employees does Mesoblast Ltd have?
About 108 as of June 30, 2026, as stated in its annual report.
Who is the CFO of Mesoblast Ltd?
James Michael Obrien, Chief Financial Officer, as named in a 4 filed July 9, 2026.
Where is Mesoblast Ltd headquartered?
Melbourne, Victoria, C3.
What is Mesoblast Ltd's stock ticker?
MESO, MEOBF on Nasdaq.
What industry is Mesoblast Ltd in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Mesoblast Ltd's website?
mesoblast.com.
Is Mesoblast Ltd a public company?
Yes. Mesoblast Ltd files with the SEC under CIK 0001345099 and trades as MESO.
Who audits Mesoblast Ltd?
PricewaterhouseCoopers, Melbourne, Australia, as named in its latest annual report (10-K).
How many shares of Mesoblast Ltd are outstanding?
1.30 billion shares as of June 30, 2026, from its 20-F filed August 27, 2026.
Have Mesoblast Ltd insiders traded stock recently?
Since April 10, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $37.5M on Forms 4 and 5. The most recent: Gregory George (Director) bought 7,910,962 shares on April 10, 2026.